The US Food and Drug Administration is requesting the removal of the “suicidal thoughts” warning from weight-loss drugs.

The U.S. Food and Drug Administration (FDA) has asked drug companies to remove warnings about the potential for suicidal thoughts from the labels of popular weight-loss and blood sugar-control drugs, including Novo Nordisk’s Wegovi and Eli Lilly’s Zipound.

The decision also includes Saxenda, an older version of the weight-loss drug produced by Novo Nordisk, following a comprehensive review by the administration that found no evidence linking the use of these drugs to an increased risk of suicidal thoughts or behaviors.

The administration said in a statement that these drugs were originally developed to treat type 2 diabetes patients, as they work by mimicking a hormone that suppresses appetite, giving a feeling of satiety and helping with weight loss.

The administration had reached a similar conclusion in a preliminary review conducted in 2024, but indicated at the time that it could not rule out a small risk due to the limited data available.

The FDA added that it recently conducted additional analyses that included extensive clinical trials, and the results showed no increase in the risk of suicidal thoughts or behavior among users of these drugs, nor did it detect an increase in other psychological side effects, such as anxiety, depression, nervousness, or psychosis.

According to the administration, the review covered 91 clinical trials involving 107,910 patients, including 60,338 patients who received blood sugar control medications, compared to 47,572 patients who received a placebo.

The administration indicated that the results of this review support the removal of previous warnings while continuing to monitor the long-term drug safety of these treatments.